Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.

Employees

1,961

Sector

Pharmaceuticals

Calendar

2024-10-28 - Q3 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
24-10-11	43.06 ¥	-8.38%	11,318,300
24-10-10	47.00 ¥	+0.43%	13,881,400
24-10-09	46.80 ¥	-10.82%	17,905,070

End-of-day quote Shenzhen S.E., October 10, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart BETTA-PHARMACEUTICALS-CO-

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

6

Last Close Price

43.06CNY

Average target price

50.10CNY

Spread / Average Target

+16.35%

Consensus

Profit revisions

estimates-change-chart BETTA-PHARMACEUTICALS-CO-

Estimate revisions

Quarterly earnings, Rate of surprise

quality-estimates-chart BETTA-PHARMACEUTICALS-CO-

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2024-10-11			5-day change	1st Jan Change
43.06 ^CNY	-8.38%		-6.33%	-16.47%

Sep. 20	Betta Pharmaceuticals to Exclusively Distribute Heyuan Biotechnology's Ofumin	MT
Aug. 05	Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Capitalization	18.02B 2.55B	P/E ratio 2024 *	37.1x	P/E ratio 2025 *	27.8x
Enterprise value	19.97B 2.83B	EV / Sales 2024 *	6.62x	EV / Sales 2025 *	5.28x
Free-Float	51.51%	Yield 2024 *	0.6%	Yield 2025 *	0.9%

Betta Pharmaceuticals to Exclusively Distribute Heyuan Biotechnology's Ofumin	Sep. 20	MT
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 05	CI
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024	May. 30	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	Jan. 03	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.	23-07-31	CI
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance	23-07-05	DJ
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing	23-06-09	MT
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023	23-06-08	CI
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China	23-05-30	MT
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC	23-05-30	CI

1 day	-8.38%
1 week	-6.33%
Current month	-6.33%
1 month	+7.22%
3 months	+32.17%
6 months	+10.50%
Current year	-16.47%

Betta Pharmaceuticals Co., Ltd. Stock

Equities

300558

CNE100002DD9

Pharmaceuticals

Valuation: Betta Pharmaceuticals Co., Ltd.

Chart: Betta Pharmaceuticals Co., Ltd.

Latest news: Betta Pharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Betta Pharmaceuticals Co., Ltd.

ETFs: Betta Pharmaceuticals Co., Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Director	Title	Age	Since
Jia Tong CEO	Chief Executive Officer	46	02-12-31
Lie Ming Ding CEO	Chief Executive Officer	60	03-01-06
Jian Xun Fan DFI	Director of Finance/CFO	53	15-12-31

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BETTA PHARMACEUTICALS CO., LTD.	-8.38%	-6.33%	-28.23%	-55.84%	2.55B
MERCK KGAA	+1.16%	+1.32%	+0.93%	-14.56%	74.72B
KYOWA KIRIN CO. LTD.	-0.68%	+0.84%	+2.22%	-28.53%	9.34B
YUHAN CORPORATION	+1.64%	+9.50%	+113.04%	+213.82%	8.94B
HALOZYME THERAPEUTICS, INC.	+1.67%	-10.44%	+42.05%	+42.40%	6.71B
SK BIOPHARMACEUTICALS CO., LTD.	+7.68%	+8.77%	+41.93%	+17.80%	6.83B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-3.40%	-8.85%	+17.87%	+15.03%	2.27B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-6.71%	-18.49%	-24.84%	+45.68%	2.16B
SUPERNUS PHARMACEUTICALS, INC.	+3.48%	+3.06%	+21.95%	+16.12%	1.82B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-4.38%	-7.97%	-56.04%	-70.14%	1.65B
Average	-0.79%	-3.19%	+13.09%	+18.18%	11.7B
Weighted average by Cap.	+0.98%	+0.65%	+13.10%	+7.42%

	2024 *	2025 *
Net sales	3.02B 427M	3.69B 522M
Net income	486M 68.72M	649M 91.82M
Net Debt	1.95B 277M	1.48B 210M